Full-Time

Head of Field Medical

Confirmed live in the last 24 hours

Relay Therapeutics

Relay Therapeutics

201-500 employees

Biotech company focused on drug discovery

Biotechnology
Healthcare

Senior

Remote in USA

Candidates must be based in the USA.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary

You match the following Relay Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Advanced degree preferred (PharmD, PhD, MD); other relevant clinical backgrounds (NP, PA, RPh) considered with strong industry experience.
  • 5+ years of experience in biotech or pharma, with at least 2+ years in a leadership role within Medical Affairs.
  • Strong solid tumor oncology experience, ideally in breast cancer and/or precision medicine.
  • Proven ability to lead, mentor, and develop MSL teams, fostering a culture of collaboration, accountability, and scientific excellence.
  • Deep understanding of the oncology treatment landscape, clinical research, regulatory environment, and HCP engagement strategies.
  • Exceptional communication and relationship-building skills, with the ability to influence across functions and levels.
  • Ability to travel up to 50%, including overnight stays for field visits, internal meetings, and medical congresses.
Responsibilities
  • Lead & Develop a High-Performing Team – Recruit, coach, and mentor a team of global MSLs (full-time and consultants), ensuring they are effective scientific ambassadors and strategic field partners.
  • Set & Execute Field Strategy – Develop and oversee the MSL engagement strategy, ensuring alignment with company priorities and trial objectives.
  • Drive Thought Leader Engagement – Expand and deepen relationships with oncologists, clinical trial investigators, and community HCPs to support scientific exchange and trial awareness.
  • Gather & Share Field Insights – Capture critical insights from HCP interactions and relay them to internal teams to help refine strategy, clinical trial design, and evidence generation.
  • Enhance Field Medical Resources – Oversee the development and compliant use of medical materials to support scientific discussions.
  • Represent Relay Tx at Key Conferences & Meetings – Develop and execute a strategic approach to medical congresses, investigator meetings, and advisory boards, ensuring impactful participation from the field team.
  • Collaborate Cross-Functionally – Partner with Medical Affairs, Clinical Development, and Regulatory teams to ensure a seamless and impactful medical strategy.
  • Ensure Compliance & Scientific Integrity – Lead the team in conducting ethical, compliant, and high-quality scientific exchanges in line with industry regulations.
  • Adapt & Evolve in a Fast-Paced Environment – Navigate the dynamic landscape of biotech and oncology, ensuring the field medical team stays agile and effective.

Relay Therapeutics focuses on drug discovery by emphasizing the movement of proteins in its research. The company uses its Dynamo™ platform, which integrates experimental and computational methods, to identify and develop new drugs, particularly for complex diseases that are hard to treat with current therapies. This platform enables Relay to target proteins that have previously been difficult to address, expanding treatment options in areas like precision oncology and genetic diseases. Unlike many competitors, Relay's approach is centered on understanding protein dynamics, which allows for more effective drug development. The company aims to deliver impactful medicines to patients and is engaged in clinical trials to ensure the safety and effectiveness of its drug candidates.

Company Size

201-500

Company Stage

IPO

Total Funding

$535M

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery complements Relay's computational techniques, enhancing drug development.
  • Quantum computing integration could boost Dynamo's capabilities in drug discovery.
  • Rising personalized medicine trend aligns with Relay's precision medicine focus.

What critics are saying

  • Increased competition from VantAI threatens Relay's market position.
  • Layoffs may impact Relay's operational efficiency and research progress.
  • Reliance on public offerings suggests potential financial instability for Relay.

What makes Relay Therapeutics unique

  • Relay's Dynamo platform targets previously undruggable proteins, expanding treatment possibilities.
  • Focus on protein motion places Relay at the forefront of innovative drug discovery.
  • Relay's precision oncology approach tailors treatments to individual genetic profiles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, vision

Life, disability, & FSA

401k

Commuter benefits

Parental leave

Home office stipend

Tuition reimbursement

PTO

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

2%
Pattern of USA
Oct 7th, 2024
Job Reductions Update: Kaléo to Cut 58 Positions, Ongoing Layoffs at Stryker

Relay Therapeutics has announced it will be laying off about 10% of its workforce, impacting approximately 30 employees, as confirmed by a spokesperson in a statement to BioSpace.

Relay TX
Sep 18th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | Relay Therapeutics

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten

GlobeNewswire
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics announces pricing of public offering of common stock.

Stock Titan
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | RLAY Stock News

Relay Therapeutics announces $200M public offering of 28.5M shares at $7 each. Learn how this biotech firm plans to use the funds and what it means for investors. Closing expected Sept 12.

Tech Times New York
Sep 9th, 2024
Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics announces proposed public offering of common stock.